
What is claimed is:

1. A CSF-1R/PDGFR multi-target inhibitor for use in preventing and/or treating sarcoma.

2. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the CSF-1R/PDGFR multi-target inhibitor comprises a compound having the structure as shown in Formula (I), or a pharmaceutically acceptable salt or isotopic derivative thereof:



Formula (I)

wherein,


R^1 represents hydrogen, halogen, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, n represents 0, 1, 2, 3, or 4;

or when n is 2, the two R^1 groups in the ortho position together with the carbon atom to which they are attached form a 5-6 membered saturated or unsaturated ring, and the ring may optionally contain 0, 1, or 2 heteroatoms selected from O, N, and S; and further, the ring may optionally be substituted by 0, 1, or 2 substituents selected from C_1-C_6 alkyl or halogen;

wherein, R^a represents hydrogen or C_1-C_6 alkyl.

3. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:




wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

or R^1 and R^2 together with the carbon atom to which they are attached form a 5-6 membered saturated or unsaturated ring, and the ring may optionally contain 0, 1, or 2 heteroatoms selected from O, N, and S; and further, the ring may optionally be substituted by 0, 1, or 2 substituents selected from C_1-C_6 alkyl or halogen;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

4. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:




wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

or R^1 and R^2 together with the carbon atom to which they are attached form a 5-6 membered saturated or unsaturated ring, and the ring may optionally contain 0, 1, or 2 heteroatoms selected from O, N, and S; and further, the ring may optionally be substituted by 0, 1, or 2 substituents selected from C_1-C_6 alkyl or halogen;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

5. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:




wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

6. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:




wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

7. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:



wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;


wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

or, R^1 and R^2 together with the carbon atom to which they are attached form a 5-6 membered saturated or unsaturated ring, and the ring may optionally contain 0, 1, or 2 heteroatoms selected from O, N, and S; and further, the ring may optionally

be substituted by 0, 1, or 2 substituents selected from C_1-C_6 alkyl or halogen;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

8. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:




wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

9. The CSF-1R/PDGFR multi-target inhibitor according to claim 1, wherein the compound has a structure as shown below, or a pharmaceutically acceptable salt or isotopic derivative thereof:



wherein, R^1 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated

C_1-C_6 alkyl, or cyano;

wherein, R^2 represents hydrogen, halogen, C_1-C_6 alkyl, -OR^a, -SR^a, halogenated C_1-C_6 alkyl, or cyano;

wherein, R^a represents hydrogen, C_1-C_6 alkyl, or halogenated C_1-C_6 alkyl.

10. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein R^1 represents hydrogen, halogen, C_1-C_3 alkyl, fluoromethyl, -OR^a, -SR^a; wherein R^a represents hydrogen or C_1-C_3 alkyl.








11. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein R^2 represents hydrogen, halogen, C_1-C_3 alkyl, fluoromethyl, -OR^a, -SR^a; wherein R^a represents hydrogen or C_1-C_3 alkyl.






12. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein R^1 represents hydrogen, halogen, methyl, trifluoromethyl, methoxy, or -SCH_3.

13. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein R^1 represents hydrogen, methyl, trifluoromethyl, fluorine, chlorine, or -SCH_3.

14. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein R^2 represents hydrogen, methyl, fluorine, or chlorine.

15. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 9, wherein the compound or its pharmaceutically acceptable salt or isotopic derivative thereof is selected from any of the following:

NO.	Structure
1	
2	
3	
4	
5	
6	
7	

8	
9	
10	
11	
12	

16. The CSF-1R/PDGFR multi-target inhibitor according to any one of claims 1 to 15, wherein the sarcoma is one or more selected from osteosarcoma, soft tissue sarcoma, and hemangioma.